share_log

HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $19 Price Target

HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $19 Price Target

HC Wainwright & Co.重申买入 Theravance Biopharma,维持19美元的目标价格
Benzinga ·  2023/02/28 06:15

HC Wainwright & Co. analyst Douglas Tsao reiterates Theravance Biopharma (NASDAQ:TBPH) with a Buy and maintains $19 price target.

HC Wainwright&Co.分析师Douglas Tsao重申了Theravance Biophma(纳斯达克:TBPH)的买入,并维持19美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发